---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-064514"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2026-05-20T20:15:21+00:00"
generated_at: "2026-05-20T21:27:11.392017+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio prices $15M public offering of 7.9M shares and warrants

## Summary
- Offering of 7,895,000 shares and warrants for 7,105,500 shares at combined price $1.90.
- Gross proceeds of ~$15M; expected closing May 21, 2026.
- Warrants exercisable at $2.25 per share, six-year term from issuance.
- Net proceeds for clinical development of buntanetap in Alzheimer's and Parkinson's and working capital.
- Canaccord Genuity acting as sole bookrunner.

## SEC filing metadata
- accession: 0001104659-26-064514
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2026-05-20T20:15:21+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465926064514/0001104659-26-064514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465926064514/tm2615162d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-064514
- JSON: https://secwatch.observer/filing/0001104659-26-064514.json
- Plain text: https://secwatch.observer/filing/0001104659-26-064514.txt

## Key facts
- Material Agreements
  Annovis Bio, Inc. entered into Underwriting Agreement with Canaccord Genuity LLC valued at approximately $15 million (effective 2026-05-20).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Canaccord Genuity LLC
  - Value: approximately $15 million
  - Effective: 2026-05-20
  source text: On May 20, 2026, Annovis Bio, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”), dated as of May 20, 2026, with Canaccord Genuity LLC, as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”) (i) an aggregate of 7,895,000 shares of common stock (the “Shares”), $0.0001 par value per share (the “Common Stock”), of the Company and (ii) accompanying common stock warrants to purchase up to an aggregate of 7,105,500 shares of Common Stock (the “Warrants” and the shares of Common Stock issuable upon exercise of the Warrants, the “Warrant Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477845/000110465926064514/0001104659-26-064514-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.